RhumbLine Advisers’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$72.6M Buy
323,371
+3,187
+1% +$794K 0.06% 258
2025
Q4
$77.1M Buy
320,184
+1,247
+0.4% +$319K 0.06% 248
2025
Q3
$87.3M Buy
318,937
+11,696
+4% +$3.19M 0.07% 230
2025
Q2
$79.3M Buy
307,241
+782
+0.3% +$187K 0.07% 244
2025
Q1
$68.6M Buy
306,459
+11,324
+4% +$2.64M 0.06% 256
2024
Q4
$67.5M Sell
295,135
-13,536
-4% -$3.26M 0.06% 259
2024
Q3
$75.4M Sell
308,671
-2,946
-0.9% -$658K 0.07% 243
2024
Q2
$59.6M Sell
311,617
-18,772
-6% -$3.81M 0.06% 281
2024
Q1
$65.4M Sell
330,389
-2,316
-0.7% -$424K 0.06% 269
2023
Q4
$57.2M Sell
332,705
-2,041
-0.6% -$314K 0.06% 281
2023
Q3
$49.5M Sell
334,746
-13,070
-4% -$2.36M 0.06% 285
2023
Q2
$76M Buy
347,816
+6,930
+2% +$1.54M 0.09% 212
2023
Q1
$74.7M Buy
340,886
+17,389
+5% +$3.77M 0.09% 204
2022
Q4
$67.3M Buy
323,497
+18,652
+6% +$4.1M 0.09% 211
2022
Q3
$66.5M Buy
304,845
+25,957
+9% +$5.91M 0.1% 185
2022
Q2
$58.5M Buy
278,888
+12,546
+5% +$2.67M 0.09% 212
2022
Q1
$64.6M Sell
266,342
-16,821
-6% -$4.07M 0.08% 211
2021
Q4
$73.8M Sell
283,163
-7,176
-2% -$1.86M 0.09% 193
2021
Q3
$76.5M Sell
290,339
-11,482
-4% -$3.14M 0.1% 168
2021
Q2
$74.4M Sell
301,821
-16,553
-5% -$3.48M 0.1% 174
2021
Q1
$61.8M Sell
318,374
-20,000
-6% -$4.01M 0.08% 206
2020
Q4
$71.9M Sell
338,374
-36,646
-10% -$7.31M 0.1% 169
2020
Q3
$64.3M Sell
375,020
-26,976
-7% -$4.98M 0.1% 171
2020
Q2
$77.2M Buy
401,996
+11,143
+3% +$1.82M 0.13% 145
2020
Q1
$57.6M Buy
390,853
+27,175
+7% +$4.33M 0.12% 159
2019
Q4
$56.4M Buy
363,678
+20,142
+6% +$2.9M 0.09% 201
2019
Q3
$46.4M Sell
343,536
-903
-0.3% -$118K 0.08% 219
2019
Q2
$42M Buy
344,439
+17,284
+5% +$1.91M 0.08% 226
2019
Q1
$34M Sell
327,155
-9,912
-3% -$1.02M 0.07% 263
2018
Q4
$38.4M Sell
337,067
-11,829
-3% -$1.27M 0.08% 219
2018
Q3
$40.2M Sell
348,896
-4,218
-1% -$462K 0.08% 247
2018
Q2
$36.6M Buy
353,114
+5,227
+2% +$529K 0.07% 264
2018
Q1
$34.3M Sell
347,887
-7,723
-2% -$730K 0.07% 274
2017
Q4
$30.1M Sell
355,610
-5,310
-1% -$439K 0.06% 309
2017
Q3
$27.8M Sell
360,920
-12,371
-3% -$946K 0.06% 313
2017
Q2
$29.1M Sell
373,291
-2,400
-0.6% -$172K 0.07% 302
2017
Q1
$27M Buy
375,691
+15,971
+4% +$1.1M 0.06% 315
2016
Q4
$22.3M Buy
359,720
+34,684
+11% +$2.12M 0.06% 347
2016
Q3
$21.1M Buy
325,036
+17,039
+6% +$1.13M 0.06% 321
2016
Q2
$19.5M Buy
307,997
+5,408
+2% +$319K 0.06% 331
2016
Q1
$17.5M Sell
302,589
-7,430
-2% -$421K 0.05% 339
2015
Q4
$16.6M Buy
310,019
+2,868
+0.9% +$162K 0.05% 343
2015
Q3
$15.7M Buy
307,151
+10,723
+4% +$577K 0.05% 354
2015
Q2
$16.7M Buy
296,428
+25,131
+9% +$1.59M 0.05% 352
2015
Q1
$19.5M Buy
271,297
+14,044
+5% +$912K 0.06% 304
2014
Q4
$14.4M Sell
257,253
-1,100
-0.4% -$57.4K 0.04% 386
2014
Q3
$12.7M Sell
258,353
-4,883
-2% -$249K 0.04% 413
2014
Q2
$13.3M Sell
263,236
-29,972
-10% -$1.49M 0.04% 412
2014
Q1
$13.1M Sell
293,208
-2,501
-0.8% -$112K 0.04% 406
2013
Q4
$13.9M Sell
295,709
-16,517
-5% -$836K 0.04% 384
2013
Q3
$16.5M Buy
312,226
+55,663
+22% +$2.7M 0.05% 344
2013
Q2
$11.6M Buy
+256,563
New +$12.2M 0.04% 422

Other funds holding RMD

RhumbLine Advisers's RMD Position: Q1 2026 in Review

RhumbLine Advisers increased its ResMed (RMD) stake by 1% in Q1 2026, buying an estimated $794K and bringing the position to 323,371 shares worth $72.6M. The position accounts for 0.06% of the portfolio, ranked #258.

RhumbLine Advisers first reported a position in RMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $87.3M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • RhumbLine Advisers held 323,371 shares of ResMed worth $72.6M as of Q1 2026.
  • RhumbLine Advisers bought 3,187 ResMed shares in Q1 2026, an estimated $794K.
  • ResMed made up 0.06% of RhumbLine Advisers's portfolio in Q1 2026, its #258 holding.
  • RhumbLine Advisers first reported a position in ResMed in Q2 2013 and has held it in 52 quarters since.
  • RhumbLine Advisers's ResMed position peaked at $87.3M in Q3 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.